The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $0.29 in the prior trading day, Applied Dna Sciences Inc (NASDAQ: APDN) closed at $0.24, down -17.66%. In other words, the price has decreased by -$17.66 from its previous closing price. On the day, 1.2 million shares were traded. APDN stock price reached its highest trading level at $0.28 during the session, while it also had its lowest trading level at $0.22.
Ratios:
Our goal is to gain a better understanding of APDN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.63 and its Current Ratio is at 1.77. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH Capital on February 12, 2021, initiated with a Buy rating and assigned the stock a target price of $24.
On January 14, 2021, H.C. Wainwright reiterated its Buy rating and also upped its target price recommendation from $18 to $14.
H.C. Wainwright reiterated its Buy rating for the stock on December 18, 2020, while the target price for the stock was revised from $20 to $12.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APDN now has a Market Capitalization of 4121688 and an Enterprise Value of 1708857. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.45 while its Price-to-Book (P/B) ratio in mrq is 0.77. Its current Enterprise Value per Revenue stands at 0.19 whereas that against EBITDA is -0.14.
Stock Price History:
The Beta on a monthly basis for APDN is 0.17, which has changed by -0.7611761 over the last 52 weeks, in comparison to a change of 0.22640884 over the same period for the S&P500. Over the past 52 weeks, APDN has reached a high of $1.86, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -50.63%, while the 200-Day Moving Average is calculated to be -73.29%.
Shares Statistics:
The stock has traded on average 135.50K shares per day over the past 3-months and 14050 shares per day over the last 10 days, according to various share statistics. A total of 16.98M shares are outstanding, with a floating share count of 14.89M. Insiders hold about 12.32% of the company’s shares, while institutions hold 18.63% stake in the company. Shares short for APDN as of 1711584000 were 270825 with a Short Ratio of 2.00, compared to 1709164800 on 268232. Therefore, it implies a Short% of Shares Outstanding of 270825 and a Short% of Float of 1.9900000000000002.
Earnings Estimates
Applied Dna Sciences Inc (APDN) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.22 and a low estimate of -$0.23, while EPS last year was $0.05. The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.17 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.63 and -$0.67 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.53, with 2.0 analysts recommending between -$0.48 and -$0.58.
Revenue Estimates
For the next quarter, 2 analysts are estimating revenue of $1.18M. There is a high estimate of $1.41M for the next quarter, whereas the lowest estimate is $950k.
A total of 2 analysts have provided revenue estimates for APDN’s current fiscal year. The highest revenue estimate was $6.1M, while the lowest revenue estimate was $3.94M, resulting in an average revenue estimate of $5.02M. In the same quarter a year ago, actual revenue was $13.37MBased on 2 analysts’ estimates, the company’s revenue will be $8.17M in the next fiscal year. The high estimate is $9.29M and the low estimate is $7.05M.
